Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000144 Helsinn Therapeutics, Inc 12/31/2020 69639010201 AKYNZEO® (fosnetupitant 235mg/ palonosetron 0.25mg) for injection (235MG/0.25MG PER VIAL) 12/31/2020 54.34 669.78 05/23/2032 Single Source Drug 3500 None The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. None n/a None None None None None None None None None None None This is a product that was launched in 2018. We are taking a planned price increase on 12/31/2020. Since this product was released in 2018, a full 5 year history is not available. Only from 2018 to present. This product was not acquired, therefore fields 14-22 are blank.
Rx0000144 Helsinn Therapeutics, Inc 09/30/2020 69639012001 Valchlor 0.02% Gel 60gm tube 09/01/2020 372.33 4555.79 07/08/2029 Single Source Drug 8575 None The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications. None None 1 03/20/2018 Actelion Pharmaceuticals, Ltd. 330000000 None None 3654.00 3355.00 2013 3165.00 None None
Rx0000119 Heron Therapeutics, Inc. 03/31/2020 47426020101 CINVANTI; 130 mg; single-dose vial 01/01/2020 7.72 359.38 09/18/2035 Single Source Drug 278108 None Increase due to market factors None There were no noted changes to the drug. None None None None None None None None None None None Product was developed by Heron
Rx0000119 Heron Therapeutics, Inc. 06/30/2020 47426020101 CINVANTI; 130 mg; single-dose vial 04/01/2020 8.09 367.47 09/18/2035 Single Source Drug 726540 None Increase due to market factors None There were no changes to the drug. None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 09/30/2020 47426020101 CINVANTI; 130 mg; single-dose vial 07/01/2020 8.27 375.74 09/18/2035 Single Source Drug 726540 None Increase due to market factors. None There were no changes to the drug. None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 12/31/2020 47426020101 CINVANTI; 130 mg; single-dose vial; injectable emulsion 10/01/2020 8.45 384.19 09/18/2035 Single Source Drug 726540 None Increase due to market factors. None There were no changes to the drug. None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 06/30/2020 47426010106 Sustol (granisetron) ER injection. 10 mg/.4mL. 6 kits/carton. 05/15/2020 94.99 3894.55 09/28/2024 Single Source Drug 100241 None Increase due to market factors None There were no changes to the drug. None None None None None None None None None None None None
Rx0000119 Heron Therapeutics, Inc. 12/31/2020 47426010106 Sustol (granisetron) ER injection. 10 mg/.4mL. 6 kits/carton. 10/01/2020 97.38 3991.92 09/28/2024 Single Source Drug 100241 None Increase due to market factors None There were no changes to the drug. None None None None None None None None None None None None
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2020 00143987825 Cefoxtin Sodium Intravenous Solution, 1GM, Vial x 25 03/14/2020 71.51 247.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2020 00143987725 Cefoxtin Sodium Intravenous Solution, 2GM, Vial x 25 03/14/2020 182.26 495.00 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2020 00143978710 Enalaprilat Intravenous Injectable, 1.25mg/1mL, Vial x10 03/14/2020 3.96 43.96 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2020 00143978610 Enalaprilat Intravenous Injectable, 1.25mg/2 mL, Vial x10 03/14/2020 7.07 78.51 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None With respect to Column 6, Patent Expiration Date; this is a generic drug and this does not apply. With respect to Columns 14-22. this product originated with Hikma and was not acquired.
Rx0000178 Hikma Pharmaceuticals USA Inc 06/30/2020 00641039112 Heparin Sodium (Porcine) Injection Solution 1000 UNIT/1ML, 25 Vials 06/19/2020 20.46 71.61 None Non-innovator Multiple Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 06/30/2020 00641245055 Heparin Sodium (Porcine) Injection Solution 1000 UNIT/30ML, 25 Vials 06/19/2020 68.00 238.00 None Non-innovator Multiple Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 06/30/2020 00641246055 Heparin Sodium (Porcine) Injection Solution 5000 UNIT/10ML, 25 Vials 06/19/2020 84.00 294.00 None Non-innovator Multiple Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2020 00641605425 Meperidine HCl Injection Solution 100 MG/ML, 25 Vials 03/17/2020 6.52 72.39 None Non-innovator Multiple Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2020 00641605225 Meperidine HCl Injection Solution 25 MG/ML, 25 Vials 03/17/2020 5.71 63.41 None Non-innovator Multiple Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178 Hikma Pharmaceuticals USA Inc 03/31/2020 00641605325 Meperidine HCl Injection Solution 50MG/ML, 25 Vials 03/17/2020 5.95 66.05 None Non-innovator Multiple Source Drug None 1 None 1 This WAC increase is not necessitated by a change or improvement in the prescription drug. None None None None None None None None None None None Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145 Horizon Therapeutics USA, Inc. 03/31/2020 75987008010 Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial 02/01/2020 1107.50 23709.50 08/03/2027 Single Source Drug None 1 None 1 None 1 01/13/2016 Crealta Holdings LLC None 1 Horizon acquired this particular product as part of the overall acquisition of Crealta Holdings LLC, and its acquisition price was incorporated into that deal’s overall purchase price of approximately $510 million with no means of individually identifying the purchase price of this asset. 14000.00 14000.00 2010 2300.00 None Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for KRYSTEXXA is not publicly available.
Rx0000145 Horizon Therapeutics USA, Inc. 03/31/2020 75987002001 Product Name: RAYOS; Product Strength: 1mg ; Dosage Form / Product Package: Delayed-release 30 tablets 02/01/2020 129.00 2762.10 08/03/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Drug was not acquired within the previous 5 years.
Rx0000145 Horizon Therapeutics USA, Inc. 03/31/2020 75987002101 Product Name: RAYOS; Product Strength: 2mg ; Dosage Form / Product Package: Delayed-release 30 tablets 02/01/2020 129.00 2762.10 08/03/2027 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Drug was not acquired within the previous 5 years.
Rx0000145 Horizon Therapeutics USA, Inc. 03/31/2020 75987002201 Product Name: RAYOS; Product Strength: 5mg ; Dosage Form / Product Package: Delayed-release 30 tablets 02/01/2020 129.00 2762.10 01/07/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Drug was not acquired within the previous 5 years.